alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                               0
<INT-BEARING-DEPOSITS>                        32676735
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                   32852787
<INVESTMENTS-CARRYING>                         8600621
<INVESTMENTS-MARKET>                           8642595
<LOANS>                                      142458340
<ALLOWANCE>                                    1613621
<TOTAL-ASSETS>                               256984306
<DEPOSITS>                                   197269328
<SHORT-TERM>                                  30330935
<LIABILITIES-OTHER>                            2418387
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        142578
<OTHER-SE>                                    26823078
<TOTAL-LIABILITIES-AND-EQUITY>               256984306
<INTEREST-LOAN>                               11953680
<INTEREST-INVEST>                              2364321
<INTEREST-OTHER>                                     0
<INTEREST-TOTAL>                              14318001
<INTEREST-DEPOSIT>                             6142487
<INTEREST-EXPENSE>                             6565434
<INTEREST-INCOME-NET>                          7752567
<LOAN-LOSSES>                                   471959
<SECURITIES-GAINS>                              479360
<EXPENSE-OTHER>                                9458960
<INCOME-PRETAX>                                 173336
<INCOME-PRE-EXTRAORDINARY>                      173336
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    365336
<EPS-PRIMARY>                                     0.12
<EPS-DILUTED>                                     0.11
<YIELD-ACTUAL>                                    4.72
<LOANS-NON>                                    1550265
<LOANS-PAST>                                    276491
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                               1241663
<CHARGE-OFFS>                                   100001
<RECOVERIES>                                         0
<ALLOWANCE-CLOSE>                              1613621
<ALLOWANCE-DOMESTIC>                           1613621
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
**AD Economic Evaluation**



### Docket No . FAA - 2012 - 0600 Directorate ID : 2012 - SW - 017 - AD Helicopter Model: Agusta S.p.A. Model AW139 Helicopters Number of Helicopters (U.S. Operators): 1 Helicopters in the US Registry . Reason : T hese actions are intended to prevent separation of the collective control rod from the torque tube, loss of control of the collective pitch, and subsequent loss of control of the helicopter. Costs : Parts per Helicopter $ Labor per Helicopter ( 8 x $ 8 5 /w ork- hour for inspecting and reassembling the control rod) $ 680 Other (Explain) Total Cost per Helicopter $ 680 Total US Fleet Cost $ 680 Executive Order 12866 : Could the AD be considered a “significant regulatory action?” Yes ( ) No (  ) DOT Regulatory Policies and Procedures : Is the AD significant? Yes ( ) Explain Below No (  ) Regulatory Flexibility Act : Will the AD have a significant economic impact on a substantial number of small entities? Yes ( ) No (  ) 

### Project Engineer : Sharon M iles
### DHS **– HSIN Advisory Committee (AC) MEETING**  **1300 Pennsylvania Avenue NW Washington, D**  **. C** **. 20004** 

**February 27 th** 



### - **28th Open to the Public and Press** 

1 

# HSIN Advisory Committee Agenda **February 27 -** **28, 2013 (**  **Day ONE**  **: February 27, 2013**  **) TIME**  **SESSION S**  **PEAKER 9:00**  **– 9:15**  **a.m. Welcome, Admin/Housekeeping**  **Issues** David Steigman **9:15 –**  **9: 35**  **a .**  **m .**  **HSIN Today: HSIN in the Real World** Katie Mullins **9: 35**  **– 1** **0: 00**  **a.m. How Far We’ve Come Since 2010:**  Jim Lanoue **10:00 –**  **10:30 a.m. HSIN R3 Value Proposition & New**  **Features** Donna Roy **10:30 –**  **10:45 a.m. Break**  **10:45 –**  **11:05 a.m. How We’ve Acted on**  **Your Recommendations Since 2010**  Donna Roy **11:05 –**  **11:30 a.m. HSIN Release 3 Requirements and**  **Development** Tracy Hollis **11:30 -**  **11:50 a.m. HSIN Outreach** **, Communications**  **& Training**  Melvin Brown II **11:50 –**  **1:00 p.m.**  **Lunch 1:00**  **– 1:25 p.m.**  **HSIN Program Management**  James Lanoue **1:30 –**  **2:15 p.m. HSIN Release 3’s Alignment to the**  **National Strategy for Information Sharing and Safeguarding**  Kshemendra Paul

**2:15 –**  **2:30 p.m. HSIN and the Office of Operations**  **Coordination** Richard Chavez **2:30 –**  **2:50 p.m. Acquisition Review Process & Portal**  **Consolidation** Denzil Thies **2:50 –**  **3: 10**  **p.m. HSIN Policy & Governance**  Michael Brody **3:10 –**  **3:25 p.m. Overall Program Status & Risk Mitigation**  Denzil Thies **3: 25**  **– 3:40**  **p.m. Break**  **3:40 –**  **4:15 p.m. Open Discussion**  David Steigman **4:15 –**  **4:4 0**  **p.m. Advisory Committee Ethics**  Mike Waters (OGC) **4:45 –**  **Open HSIN AC Member Discussions**  HSIN AC Chair/Vice Chair (Rolando Rivero, Ron Leavell) **5:00 p.m. Adjourn** 

### DHS **– HSIN Advisory Committee (AC) MEETING**  **1300 Pennsylvania Avenue NW Washington, D**  **. C** **. 20004** 

**February 27 th** 



### - **28th Open to the Public and Press** 

2 

## (Day TWO: February 28, 2013) **TIME SESSION**  **S PEAKER**  **9:00 –**  **9:15 a.m. Welcome**  Donna Roy/David Steigman **9:15 –**  **9:30 a.m. HSIN Cooperation with Other Key DHS**  **Programs** Dan Cotter **9:30 –**  **10:00 a.m.**  **HSIN Cooperation with Other Key DHS Programs P** **ar t 2**  Don Triner **10:00 a.m. Break**  **10:15 –**  **10: 4** **5 a.m. NIAC Recommendations/HSIN Impact**  Nancy Wong **1 0:45**  **– 11:** **0 5**  **a.m. HSIN Program**  **: Where We Need Your**  **Advice** James Lanoue **11: 0** **5 –**  **11: 30**  **DHS Expense Reimbursement** Leilani Cartledge **11: 30**  **– 12:30**  **p .m.**  **Lunch 12:30**  **– 1:00 p.m.**  **HSIN AC Members Formulate Recommendations**  HSIN AC Chair/Vice Chair (Rolando Rivero, Ron Leavell) **1:00 –**  **1:15 p.m. HSIN’s Progress and Challenges:**  **Program Status Update** Richard Spires **1:15 –**  **2:00 p.m.**  **HSIN AC Members Formulate Recommendations**  **(cont.)** HSIN AC Chair/Vice Chair (Rolando Rivero, Ron Leavell) **2:00 p.m. Adjourn**
Exhibit 99.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In
connection with the Quarterly Report of Southwall Technologies Inc. (the "Company") on Form 10-Q for the period ending June 30, 2002 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Robert R. Freeman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to
§ 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)  The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  The
information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

|/s/ROBERT R. FREEMANRobert R. Freeman
Chief Financial Officer
August 13, 2002 |  | 
|----------------------------------------------------------------------------- |  | 

This
Certification is made solely pursuant to the Sarbanes-Oxley Act of 2002 and shall not be deemed part of the Report or incorporated by reference into any of the Company's filings with the
Securities and Exchange Commission by implication or by any reference in any such filings to the Report.

---

QuickLinks
§ 4.103 What information must you share with other constituent part applicants for the combination product? ( a ) When you receive information regarding an event that involves a death or serious injury as described in § 803.3 of this chapter, or an adverse experience as described in § 314.80(a) of this chapter or § 600.80(a) of this chapter, associated with the use of the combination product, you must provide the information to the other constituent part applicant(s) for the combination product no later than 5 calendar days of your receipt of the information.
( b ) With regard to information you must provide to the other constituent part applicant(s) for the combination product, you must maintain records that include: ( 1 ) A copy of the information you provided,
( 2 ) The date the information was received by you,
( 3 ) The date the information was provided to the other constituent part applicant(s), and
( 4 ) The name and address of the other constituent part applicant(s) to whom you provided the information.
**Exhibit 32.2**

 

**FIRST MARINER BANCORPCERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

Pursuant to, and for purposes only of, 18 U.S.C. § 1350, I, Mark A.Keidel, Chief Financial Officer of First Mariner Bancorp (the “Company”) herebycertify that (i) the Annual Report of the Company on Form 10-K for the yearended December 31, 2004 filed with the Securities and Exchange Commission(the “Report”) fully complies with the requirements of Section 13(a) or15(d) of the Securities Exchange Act of 1934, and (ii) information contained inthe Report fairly presents, in all material respects, the financial conditionand results of operations of the Company.

 

 
| Dated: March 16, 2005 | /s/ Mark A. Keidel      |   |
|----------------------------|-------------------------|--------|
|                       | Mark A. Keidel          |
|                       | Chief Financial Officer |

 

----
§ 520.530 Cythioate oral liquid. ( a ) *Specifications.* Each milliliter contains 15 milligrams of cythioate.
( b ) *Sponsor.* See Nos. 054771 and 058198 in § 510.600 of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* 15 milligrams cythioate per 10 pounds of body weight every third day or twice a week.
( 2 ) *Indications for use.* Dogs, for control of fleas.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[49 FR 5614, Feb. 14, 1984, as amended at 67 FR 78355, Dec. 24, 2002; 79 FR 28819, May 20, 2014; 86 FR 14818, Mar. 19, 2021; 87 FR 58961, Sept. 29, 2022]
§ 520.2138 Spironolactone and benazepril. ( a ) *Specifications.* Each chewable tablet contains 20 milligrams (mg) spironolactone and 2.5 mg benazepril hydrochloride, 40 mg spironolactone and 5 mg benazepril hydrochloride, or 80 mg spironolactone and 10 mg benazepril hydrochloride.
( b ) *Sponsor.* See No. 013744 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer orally once daily, with food, at a dose of 0.9 mg per pound (lb) (2 mg per kilogram (kg)) spironolactone and 0.11 mg/lb (0.25 mg/kg) benazepril hydrochloride, according to dog body weight using a suitable combination of whole and/or half tablets.
( 2 ) *Indications for use.* With concurrent therapy (*e.g.,* furosemide, etc.) for the management of clinical signs of mild, moderate, or severe congestive heart failure in dogs due to atrioventricular valvular insufficiency (AVVI).
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[86 FR 14819, Mar. 19, 2021]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

      ( print page 8373)    
                    Notice is hereby given of a change in the meeting of the National Cancer Institute Board of Scientific Advisors, March 8, 2010, 8 a.m. to March 9, 2010, 12 p.m., National Institutes of Health, Building 31, 31 Center Drive, Bethesda, MD 20892 which was published in the                     **Federal Register**                     on January 20, 2010, 75FR3243.                

                    This                     **Federal Register**                     Notice is amended to change the meeting to a one day meeting to be held on March 8, 2010, 8 a.m. to 6 p.m. The meeting is open to the public.                

Dated: February 18, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-3748 Filed 2-23-10; 8:45 am]

BILLING CODE 4140-01-P
§ 520.1803 Piperazine citrate capsules. ( a ) *Specifications.* Each capsule contains piperazine citrate equivalent to 140 milligrams of piperazine base.
( b ) *Sponsor.* See No. 021091 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* The contents of 1 capsule should be mixed with the food of the animal for each 5 pounds, or fraction thereof of body weight, except dogs weighing over 25 pounds should be given the contents of 6 capsules. The drug should be mixed in 1/2 of the regular feeding and when the animal has finished eating the dosed food, the remainder of the food may be given. Dogs and cats may be wormed at 6 to 8 weeks of age. The first treatment should be repeated 10 days later. Reinfection may occur. Repeat treatment if indicated.
( 2 ) *Indications for use.* For the removal of large roundworms (*Toxocara canis* and *Toxascaris leonina*).
( 3 ) *Limitations.* Severely debilitated animals should not be treated except on the advice of a veterinarian.
[40 FR 13838, Mar. 27, 1975, as amended at 54 FR 38515, Sept. 19, 1989; 78 FR 28826, May 20, 2014]
Exhibit
15.2








To the
Partners of


Icahn
Enterprises L.P.





We are
aware of the inclusion in Icahn Enterprises L.P.’s Form 10-Q for the quarter
ended September 30, 2010 and the incorporation by reference in the Registration
Statements (Form S-3 Nos. 333-143930 and 333-158705 and Form S-4 No. 333-166139)
of Icahn Enterprises L.P. of our report dated October 28, 2010 relating to the
unaudited consolidated interim financial statements of Federal-Mogul Corporation
that are included in Federal-Mogul Corporation’s Form 10-Q for the quarter ended
September 30, 2010.





/s/ Ernst
and Young LLP





Detroit,
Michigan


November
4, 2010
[Cite as Disciplinary Counsel v. Golden, ___ Ohio St.3d ___, 2022-Ohio-1865.]

DISCIPLINARY COUNSEL v. GOLDEN.

[Cite as Disciplinary Counsel v. Golden, ___ Ohio St.3d ___, 2022-Ohio-1865.]

(No. 2012-0764—June 1, 2022—Decided June 3, 2022.)

ON APPLICATION FOR REINSTATEMENT.

____________________

{¶ 1} This cause came on for further consideration upon the filing of an 

application for reinstatement by respondent, Kenneth Louis Golden, Attorney 

Registration No. 0078441, last known address in West Hollywood, California.

{¶ 2} The court coming now to consider its order of July 12, 2012, wherein 

the court, pursuant to former Gov.Bar R. V(11), suspended respondent from the 

practice of law for a period of two years with twenty-one months stayed and ordered 

that he would not be reinstated to the practice of law in Ohio until he was reinstated 

to the practice of law in the state of California, finds that respondent has complied 

with that order and with the provisions of Gov.Bar R. V(24).

{¶ 3} Therefore, it is ordered by this court that respondent is reinstated to 

the practice of law in the state of Ohio.

{¶ 4} It is further ordered that the clerk of this court issue certified copies 

of this order as provided for in Gov.Bar R. V(17)(E)(1) and that publication be 

made as provided for in Gov.Bar R. V(17)(E)(2).

{¶ 5} For previous case, see Disciplinary Counsel v. Golden, 132 Ohio 

St.3d 1236, 2012-Ohio-3149, 972 N.E.2d 599.

O’CONNOR, C.J., and KENNEDY, FISCHER, DEWINE, DONNELLY, STEWART,

and BRUNNER, JJ., concur.

_________________
§ 524.815 Eprinomectin and praziquantel. ( a ) *Specifications.* Each milliliter (mL) of solution contains 4 milligrams (mg) eprinomectin and 83 mg praziquantel.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Conditions of use in cats* — ( 1 ) *Amount.* Using the 0.3 mL and 0.9 mL unit applicators, administer a minimum dose of 0.23 mg eprinomectin per pound body weight and 4.55 mg praziquantel per pound body weight by topical application on the dorsal midline between the base of the skull and the shoulder blades.
( 2 ) *Indications for use.* For the prevention of heartworm disease caused by *Dirofilaria immitis,* and for the treatment and control of roundworms (adult and fourth stage larval *Toxocara cati*), hookworms (adult and fourth stage larval *Ancylostoma tubaeforme;* adult *Ancylostoma braziliense*), and tapeworms (adult *Dipylidium caninum* and *Echinococcus multilocularis*), in cats and kittens 7 weeks of age and older and 1.8 lbs or greater.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[83 FR 48946, Sept. 28, 2018, as amended at 84 FR 39184, Aug. 9, 2019]
#### § 520.905 Fenbendazole oral dosage forms.
Exhibit 23  Consent of Independent
Registered Public Accounting Firm  The Board of Directors
Ballantyne Strong, Inc.:  We
consent to the incorporation by reference in the registration statements (File
Nos. 333-03849, 333-116739, 333-139177, and 333-153408) on Form S-8 of
Ballantyne Strong, Inc. (the Company) of our report dated March 23, 2010
with respect to the consolidated balance sheets of Ballantyne Strong, Inc.
and subsidiaries as of December 31, 2009 and 2008, and the related
consolidated statements of operations, stockholders equity and comprehensive
income (loss), and cash flows for each of the years in the three-year period
ended December 31, 2009, and the related financial statement
schedule II, which report appears in the December 31, 2009 annual report
on Form 10-K of Ballantyne Strong, Inc.   Omaha,
Nebraska
March 23, 2010
Editorial Note on Part 177
Editorial Note: Nomenclature changes to part 177 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 177.2465 Polymethylmethacrylate/poly(trimethoxysilylpropyl)methacrylate copolymers. Polymethylmethacrylate/poly(trimethoxysilylpropyl) methacrylate copolymers (CAS Reg. No. 26936-30-1) may be safely used as components of surface primers used in conjunction with silicone polymers intended for repeated use and complying with § 175.300 of this chapter and § 177.2600, in accordance with the following prescribed conditions. ( a ) *Identity.* For the purpose of this section, polymethylmethacrylate/poly(trimethoxysilylpropyl)methacrylate copolymers are produced by the polymerization of methylmethacrylate and trimethoxysilylpropylmethacrylate.
( b ) *Conditions of use.* ( 1 ) The polymethylmethacrylate/poly(trimethoxysilylpropyl)methacrylate copolymers are used at levels not to exceed 6.0 percent by weight of the primer formulation.
( 2 ) The copolymers may be used in food contact applications with all food types under conditions of use B through H as described in table 2 of § 176.170(c) of this chapter.
[59 FR 5948, Feb. 9, 1994]
**Exhibit 32**

 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED**

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

Thecertifications set forth below are hereby submitted to the Securities andExchange Commission pursuant to, and solely for the purpose of complying with, Section 1350of Chapter 63 of Title 18 of the United States Code in connection with thefiling on the date hereof with the Securities and Exchange Commission of theQuarterly Report on Form 10-Q of the Company for the quarterended March 31, 2008.

 

Eachof the undersigned hereby certifies in his capacity as an officer of CitizensBancshares Corporation and subsidiary (the “Company”) that, to his knowledge onthe date of this certification, the Quarterly Report of the Company on Form 10-Qfor the period ended March 31, 2008 fully complies with the requirementsof Section 13(a) or 15(d) of the Securities Exchange Act of 1934 andthat the information contained in such report fairly presents, in all materialrespects, the financial condition of the Company at the end of such period andthe results of operations of the Company for such period.

 

 
| Date:  | May 13, 2008 | By:                                    | /s/ James E. Young |
|--------|-------------------|----------------------------------------|--------------------|
|   |              | James E. Young                         |
|   |              | President and Chief  Executive Officer |
|   |              |                                   |
|   |              |                                   |
| Date:  | May 13, 2008 | By:                                    | /s/ Cynthia N. Day |
|   |              | Cynthia N. Day                         |
|   |              | Senior Executive Vice  President and   |
|   |              | Chief Operating Officer                |
|   |              |                                   |
|   |              |                                   |
| Date:  | May 13, 2008 | By:                                    | /s/ Samuel J. Cox  |
|   |              | Samuel J. Cox                          |
|   |              | Executive Vice President  and          |
|   |              | Chief Financial Officer                |

 

----